Table 2 Characteristics of applied therapy
From: QTc and psychopharmacs: are there any differences between monotherapy and polytherapy
Group 1 (N = 32) | Group 2 (N = 29) | ||||
|---|---|---|---|---|---|
Psychotropic drug | Patients in monotherapy | Patients in polytherapy | |||
N of patients | dose range (mg/d) | N of patients | dose range(mg/d) | ||
AD used | |||||
Antipsychotic | |||||
Ziprasidone | 3 | 120–160 | 1 | 120 | map |
Olanzapine | 4 | 10–20 | 7 | 5–15 | Mir,ven,par,fluo |
Clozapine | 1 | 100 | - | - | - |
Risperidone | 3 | 3–5 | 1 | 4 | map |
Sulpiride | 1 | 400 | 3 | 50–200 | ser,clo |
fluophenazine | 7 | 5–8 | 6 | 2–15 | tia,ser,par,map |
Haloperidol | 3 | 6–15 | 4 | 4–15 | mir,map,esc,clo |
Promazine | - | - | 4 | 75–350 | tia,ven,map |
Quetiapine | - | - | 2 | 300–500 | par,fluo |
zuclopenthixol | - | - | 1 | 10 | Fluo |
AP used | |||||
Antidepressant | |||||
Mirtazapine | 2 | 30 | 3 | 15–30 | ol,hal |
Fluvoxamine | 1 | 150 | - | - | - |
Tianeptin | 2 | 37.5 | 2 | 37.5 | flu,pro, |
Sertraline | 2 | 50–100 | 2 | 50 | sul,flu |
Venlafaxine | 2 | 37.5–75 | 4 | 37.5–150 | ol,pro |
Paroxetine | - | - | 4 | 10–40 | Ol,flu,que |
Maprotiline | 1 | 100 | 7 | 50–100 | zip,ris,flu,hal |
Fluoxetine | - | - | 3 | 20–40 | ol,que,zuc |
escitalopram | - | - | 1 | 15 | Hal |
clomipramine | - | - | 3 | 25 | sul,hal |